Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 5 days ago Drug news

FDA approves Siliq (brodalumab) to treat moderate-to-severe plaque psoriasis.-Valeant Pharma Intl.

The FDA has approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq...

Added 1 month ago Drug news

Rhofade cream (oxymetazoline HCI cream 1.0%) approved by FDA for persistent facial erythema associated with rosacea- Allergan

Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...

Added 1 month ago Drug news

Phase III trial of CHS 1420, (adalimumab biosimilar) meets primary endpoint in psoriasis- Coherus BioSciences

Coherus BioSciences reported results from an ongoing 3-Part, Phase III clinical study of CHS 1420, (adalimumab biosimilar) candidate in psoriasis....

View all news articles

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

Guidelines

Adalimumab for the treatment of adults with psoriasis

The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition...

Added 6 days ago

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course, and is associated with joint disease in approximately 25% of patients.

Added 6 days ago

Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis

To provide the dermatologist a guide focuses specifically on the diagnosis and management of the diseases most often found in patients with psoriasis.

Added 6 days ago

View all guidelines

Journal articles

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T(H)17) subset of T(H) cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental ...

Added 2 days ago

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

The articles by Papp and colleagues and Leonardi and colleagues (both in the March 29 issue) attest to the growing interest in the therapeutic potential of agents such as ixekizumab and...

Added 2 days ago

Treatment with the interleukin-17a-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomised single-center study

Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.

Added 2 days ago

View all journal articles

Clinical trials

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...

Added 1 day ago

A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....

Added 1 day ago

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Added 5 days ago

View all clinical trials